Replies to post #3919 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[ash111]

2.4B and KIT-302 much better."Lead Drug Candidate Addresses Multi Billion $ Market With Better Alternative
KIT-302 offers a superior alternative for patients, doctors, and payors for the treatment of pain
caused by osteoarthritis and hypertension. Osteoarthritis is the most common form of arthritis,
causing significant physical pain and decreased mobility. Pain medications for osteoarthritis
account for billions of dollars in sales globally. Most of these drugs, including celecoxib, are
NSAIDs which have the side effect of increasing hypertension. Of the 27 million Americans who
live with osteoarthritis, 13.5 million also suffer from hypertension, which increases the risk of
heart attack, stroke, and death. KIT-302 combines an effective, safe hypertension drug
amlodipine (the active ingredient in Pfizer's Norvasc®) with celecoxib (the active ingredient in
Pfizer’s Celebrex®), which had global sales of $2.7 billion in 2014. Based on a recent U.S. Market
Assessment commissioned by Kitov, physicians stated they would prescribe KIT-302 to 40% of
their osteoarthritis patients currently using celecoxib and to 25% of osteoarthritis patients not
using celecoxib. Third party payors, including insurers, reacted very positively to KIT-302 based on
estimated pricing and improved compliance, which is estimated by Kitov to potentially save the
U.S. healthcare system $650 million annually.